. . . . . . . "[A phase II study of the peroxisome proliferator-activated receptor-? agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer's disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-?4-negative subjects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:15:35+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .